2020
Neoadjuvant Chemotherapy or Chemoradiotherapy Does Not Increase Early and Late Post-operative Complication Rates Following Definitive Resection for Pancreatic Ductal Adenocarcinoma
Deig C, Stratton A, Trone K, Beneville B, Liu A, Kanwar A, Bassale S, Chen Y, Grossblatt-Wait A, Attia F, Sheppard B, Keith D, Chen E, Lopez C, Billingsley K, Gilbert E, Nabavizadeh N, Thomas C, Grossberg A. Neoadjuvant Chemotherapy or Chemoradiotherapy Does Not Increase Early and Late Post-operative Complication Rates Following Definitive Resection for Pancreatic Ductal Adenocarcinoma. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e606-e607. DOI: 10.1016/j.ijrobp.2020.07.1845.Peer-Reviewed Original ResearchPhase II study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma.
Chen E, Tormoen G, Kardosh A, Nabavizadeh N, Foster B, Mayo S, Billingsley K, Gilbert E, Lanciault C, Grossberg A, Bensch K, Maynard E, Anderson E, Sheppard B, Thomas C, Lopez C, Vaccaro G. Phase II study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma. Journal Of Clinical Oncology 2020, 38: 697-697. DOI: 10.1200/jco.2020.38.4_suppl.697.Peer-Reviewed Original ResearchGemcitabine/nab-paclitaxelPancreatic ductal adenocarcinomaResectable pancreatic ductal adenocarcinomaPre-operative therapyPre-operative treatmentNab-paclitaxelPancreatic resectionDuctal adenocarcinomaBorderline resectable pancreatic ductal adenocarcinomaSingle-arm phase II trialNab-paclitaxel chemotherapyPositive clinical nodesPhase II studyR0 resection ratePhase II trialNegative surgical marginsRelapse-free survivalMicro-metastatic diseaseIntensity-modulated radiation therapyGemcitabine 1000II trialPrimary endpointResection rateSecondary endpointsII study
2011
A Nomogram for Predicting the Benefit of Adjuvant Therapy for Resected Pancreatic Ductal Adenocarcinoma
Bicquart C, Youssef R, Wissel A, Sheppard B, Billingsley K, Thomas C, Wang S. A Nomogram for Predicting the Benefit of Adjuvant Therapy for Resected Pancreatic Ductal Adenocarcinoma. International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s561. DOI: 10.1016/j.ijrobp.2011.06.887.Peer-Reviewed Original Research
2009
Effect of Chemoradiation on Survival of Resected Pancreatic Ductal Adenocarcinoma with Close or Positive Margins
Bicquart C, Youssef R, Sheppard B, Corless C, Billingsley K, Thomas C. Effect of Chemoradiation on Survival of Resected Pancreatic Ductal Adenocarcinoma with Close or Positive Margins. International Journal Of Radiation Oncology • Biology • Physics 2009, 75: s291-s292. DOI: 10.1016/j.ijrobp.2009.07.671.Peer-Reviewed Original Research